Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line pucotenlimab versus investigator's choice chemotherapy in MSI-H/dMMR metastatic colorectal cancer
CTR20222431Phase 3Active
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pucotenlimab in colorectal cancer (CRC), microsatellite unstable colorectal cancer, sponsored by Lepu Biopharma Co., Ltd.. Started May 2023; status: active.
02
Drugs
pucotenlimab
03
Conditions
colorectal cancer (CRC)microsatellite unstable colorectal cancer
Beyond the preview
Go deeper on CTR20222431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222431.